Pharmacokinetics and pharmacodynamic biomarkers in early oncology drug development

European Journal of Cancer

Volumn 45, Issue SUPPL. 1, 2009, Pages 436-438

  Takimoto, Chris H ^a  

^a Ortho Biotech Oncology Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; TUMOR MARKER;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BIOASSAY; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL PHARMACOLOGY; DECISION MAKING; DRUG MECHANISM; HUMAN; PRIORITY JOURNAL; QUALITY CONTROL;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DESIGN; DRUG EVALUATION; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70349115987     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(09)70080-2     Document Type: Article

References (5)

1. Goulart B.H., Clark J.W., Pien H.H., Roberts T.G., Finkelstein S.N., and Chabner B.A. Trends in the use and role of biomarkers in phase I oncology trials. Clin Cancer Res 13 (2007) 6719-6726
2. Ratain M.J., and Glassman R.H. Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?. Clin Cancer Res 13 (2007) 6545-6548
3. Workman P. Auditing the pharmacological accounts for Hsp90 molecular chaperone inhibitors: unfolding the relationship between pharmacokinetics and pharmacodynamics. Mol Cancer Ther 2 (2003) 131-138
4. Luo F.R., Yang Z., Dong H., et al. Prediction of active drug plasma concentrations achieved in cancer patients by pharmacodynamic biomarkers identified from the geo human colon carcinoma xenograft model. Clin Cancer Res 11 (2005) 5558-5565
5. Yamazaki S., Skaptason J., Romero D., et al. Pharmacokinetic-pharmacodynamic modeling of biomarker response and tumor growth inhibition to an orally available cMet kinase inhibitor in human tumor xenograft mouse models. Drug Metab Dispos 36 (2008) 1267-1274